MTOR and cancer: Pre-clinical studies have suggested that metformin inhibits cancer progression and prognosis via direct effects on the cancer cells, by acting on the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway, and indirect effects by decreasing serum levels of insulin and insulin-like growth factor 1 (IGF-1).